A phase 1b/pharmacokinetic trial of PTC299, a novel posttranscriptional VEGF inhibitor, for AIDS-related Kaposi's Sarcoma: AIDS malignancy consortium trial 059

for the AIDS Malignancy Consortium (AMC)-059 Study Team

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'A phase 1b/pharmacokinetic trial of PTC299, a novel posttranscriptional VEGF inhibitor, for AIDS-related Kaposi's Sarcoma: AIDS malignancy consortium trial 059'. Together they form a unique fingerprint.

Medicine & Life Sciences